About us

SolaranRx: The Melanoma Game Changer

SolaranRx is an emerging growth company developing a new class of therapies and companion imaging agents to treat metastatic melanoma. The new technology platform offers distinctive therapeutic potential while avoiding the shortcomings of existing therapies. SolaranRx merges therapeutics and diagnostics into a Precision Theranostic Platform™ with a distinctive mechanism of action and minimal side effects, giving new options to clinicians and more hope to patients.

The Problem
Seventy-five percent of patients with advanced melanoma are dead within one year. A majority of patients do not respond to current therapies and side effects can be so severe that treatment must be withdrawn. Many patients try multiple therapies in search of one that may work, losing valuable time and dramatically increasing their chances of succumbing to this deadly disease.

SolaranRx’s Solution
SolaranRx has developed a Precision Theranostic Platform™ that precisely targets deadly metastatic melanoma tumors with a radiolabeled peptide, offering unique therapeutic potential with minimal side effects. This novel peptide technology demonstrates a highly specific binding to melanoma cells enabling physicians to identify patients for treatment through an imaging procedure, deliver targeted radiation to kill melanoma cells and visualize patient response. This approach has been validated in accepted melanoma animal models, resulting in three “composition of matter” U.S. patents with other applications in process. SolaranRx is focused on developing its lead product SRX-1177, which has been granted Orphan Drug designation by the FDA based on compelling pre-clinical evidence.

Market Opportunity
According to GlobalData, the global melanoma drug market will grow at an annual rate of 15.5% reaching $5.6 billion by 2023, with the United States representing 60% market share. A significant market opportunity exists for SolaranRx by its positioning as a unique, safer alternative to current therapies.

Competitive Advantages

• Distinctive mechanism of action creates a new class of treatment
• Imaging scan determines individual patient suitability for treatment
• Fewer side effects than existing therapies
• More cost effective than existing therapies
• Issued patents

Starting in 2011, Bristol-Myers Squibb, Roche, Merck, and GSK introduced immunotherapy and targeted therapy drugs to treat advanced melanoma. No radiopharmaceuticals or peptides are currently on the market or in clinical trials for metastatic melanoma. SolaranRx has an exciting first mover opportunity to establish a new class of precision medicine to address a large unmet need.